Latest stories
Featured
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic®...
Press Release, Business Development
12 February 2024
- Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’, outlook stable Press Release, Corporate 29 May 2025 Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’, outlook stable
- Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection Press Release, Product 27 May 2025 Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
- Hikma announces strong medium-term Group guidance ahead of its US site visit Press Release, Corporate 15 May 2025 Hikma announces strong medium-term Group guidance ahead of its US site visit
- Hikma announces settlement agreement for Xyrem® (sodium oxybate) U.S. class action lawsuits Press Release, Corporate 08 May 2025 Hikma announces settlement agreement for Xyrem® (sodium oxybate) U.S. class action lawsuits
Related content